OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
OKYO Pharma Limited, a biopharmaceutical company, is making strides in developing treatments for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), conditions currently lacking in effective therapies. Their lead candidate, OK-101, has shown promising results in Phase 2 trials, demonstrating significant improvements in DED symptoms with a favorable safety profile. The company is also preparing to commence a Phase 2 trial for OK-101 in treating NCP, highlighting its potential to address unmet medical needs in ophthalmology.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
